Neisseria meningitidis serogroup B is the most prevalent cause of invasive 
meningococcal disease in Europe and members of laboratories working on 
meningococci are at risk due to frequent handling. Recommendation for 
anti-meningococcal vaccination among these workers has been recently updated 
upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity 
and safety of this vaccine among adults laboratory staff using the recommended 
schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite 
of frequent local side effects and all participants reported at least one side 
effect after each dose. Immunogenicity was evaluated 6 weeks and one year after 
the second dose. All participants showed increase in their bactericidal titers 
against the components of the vaccine 6 weeks after the second dose, however 
titers declined significantly one year later.